Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Advanced Biomed Inc. (ADVB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including registration statements, current reports, and notifications related to its Nasdaq listing. Advanced Biomed is a Nevada-incorporated biotechnology company focused on cancer diagnostics, microfluidic biochips, and precision medicine tools, and its filings offer detailed insight into its capital structure, risk factors, and operational footprint.
Key documents for ADVB include its Form S-1 registration statements, which describe the company’s initial public offering on the Nasdaq Capital Market and an equity line of credit arrangement with a selling stockholder. These filings outline the company’s microfluidic technology platform, devices such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, associated biochips and immunostaining kits, and products like A+LCGuard for early lung cancer screening. They also discuss legal and operational risks tied to subsidiaries in Taiwan, Hong Kong, and Shanghai.
Users can also review Form 8-K current reports, where Advanced Biomed discloses material events such as the launch of the A+PerfusC integrated perfusion 3D cell culture platform and receipt of a Nasdaq notice regarding minimum bid price requirements for continued listing. A Form 12b-25 (NT 10-Q) notification of late filing explains timing for a quarterly report and notes that the company did not anticipate significant changes in results of operations for the referenced period.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand financing arrangements, listing status, operational risks, and technology descriptions. Real-time updates from EDGAR, along with structured access to forms such as S-1, 8-K, and 12b-25, make this page a focused resource for analyzing ADVB’s regulatory history and disclosures.
Advanced Biomed Inc. entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, which provides AI-powered financial verification and audit solutions. The seller will receive 270,000 shares of Advanced Biomed common stock, valued at $4.00 per share, for an estimated total of $1,080,000.
The acquisition is conditioned on completing financial and legal due diligence of Acellent and obtaining all required regulatory approvals, so the transaction has not yet closed.
Advanced Biomed Inc. reported leadership changes effective March 25, 2026. Steven I-Fang Cheng resigned as both a member of the Board of Directors and as Chief Technology Officer. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the Board, following a recommendation from the Nominating Committee, appointed Chief Financial Officer Mingze Yin as a director. The company disclosed that Mr. Yin has no family relationships with other leaders, no special arrangements leading to his appointment, and no related-party transactions requiring disclosure.
Advanced Biomed Inc. reported that Nasdaq has determined the company regained compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company implemented a reverse stock split completed on February 20, 2026, after shareholders approved the action on January 12, 2026.
Following the reverse split, the company’s common stock maintained a closing bid of at least $1.00 per share, satisfying Nasdaq’s rule. As a result, Advanced Biomed’s stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor under Listing Rule 5815(d)(4)(A).
Advanced Biomed Inc. implemented a 1-for-20 reverse stock split of its common stock, effective at the open of trading on February 20, 2026, to consolidate every 20 issued and outstanding shares into 1 share with the same par value.
The capital structure change does not alter the number of authorized shares and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement. After the reverse split, total issued and outstanding common shares change from 27,290,710 to approximately 1,364,536, while the stock continues trading on the Nasdaq Capital Market under the symbol ADVB.
Advanced Biomed Inc. reported net income of $6.47M for the six months ended December 31, 2025, a sharp improvement from a prior-year loss. This turnaround was driven almost entirely by a $7.35M gain on selling its Hong Kong subsidiary and related China operations, which are now classified as discontinued.
From continuing operations the company generated income of $6.74M, while discontinued operations produced a loss of $0.27M. Operating expenses remained modest at $0.79M over six months, reflecting a lean cost base focused on research and development and general and administrative activities.
Despite the reported profit, Advanced Biomed used $1.12M of cash in operating activities and ended the period with cash of $2.60M. Total assets were $10.85M and total liabilities fell to $1.37M, leaving stockholders’ equity of $9.48M, largely helped by the deconsolidation gain.
Management disclosed that the positive earnings are mainly one-time and that recurring operations still consume cash, leading to “substantial doubt” about the company’s ability to continue as a going concern. To support liquidity, Advanced Biomed highlighted its prior IPO and a $25M equity line of credit agreement with an institutional investor, as well as subsequent share issuances in January 2026.
Advanced Biomed Inc. filed an amended current report describing share issuance tied to a previously disclosed equity line of credit. The company has an agreement with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. for an equity line of up to $25,000,000 in common stock.
On January 30, 2026, Advanced Biomed issued 1,650,710 shares of common stock to the investor as a commitment fee under the agreement, with an aggregate value of $500,000 at the time of issuance. These shares were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act of 1933.
Advanced Biomed Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors on January 28, 2026, to issue and sell 4,000,000 shares of common stock at $0.062 per share, for total proceeds of $248,000.
The transaction closed and the shares were issued on January 29, 2026. The shares were sold in a private placement relying on exemptions from U.S. registration under Section 4(a)(2) of the Securities Act and Regulation S.
Advanced Biomed Inc. entered into a Supplemental Agreement related to its previously announced spin-off of Advanced Biomed (HK) Limited. The Hong Kong subsidiary acknowledged that it owes the company an aggregate $6,925,549, reflecting its accounts receivable as of the original spin-off date and the new agreement date.
Under this Supplemental Agreement, Advanced Biomed (HK) Limited irrevocably agrees to repay the entire debt on or before the first anniversary of January 26, 2026. This supplements the prior deal in which Advanced Biomed agreed to sell 100% of the Hong Kong subsidiary’s shares for an aggregate purchase price of US$23,000. The board of directors unanimously approved the Supplemental Agreement.
Advanced Biomed Inc. obtained written consent from stockholders holding approximately 79.92% of its voting power to approve a reverse stock split of its common stock. The Board is authorized to implement a reverse split at a ratio ranging from 1-for-2 to 1-for-100, in its sole discretion, to increase the per-share trading price and help maintain the company’s listing on The Nasdaq Capital Market.
As of January 8, 2026, the company had 21,640,000 shares of common stock outstanding. The reverse split will reduce the number of shares each investor holds but is intended to leave each stockholder’s percentage ownership generally unchanged, with fractional shares rounded up to the nearest whole share. No change will be made to the number of authorized shares or the $0.001 par value. The action was approved by the Board on January 7, 2026 and will not become effective until after February 12, 2026, with the company currently anticipating an effective date of February 13, 2026 or a later date specified in a Certificate of Amendment filed in Nevada.
Advanced Biomed Inc. reported that it has failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share by the January 14, 2026 compliance deadline. Nasdaq staff has notified the company that its common stock is scheduled for delisting and trading suspension on January 27, 2026 unless the decision is reversed.
The company appealed the delisting notice on January 21, 2026, which temporarily stayed any suspension and the filing of a Form 25-NSE while a Nasdaq Hearings Panel reviews the case. Advanced Biomed plans to present a remediation plan, including a reverse stock split that stockholders approved on January 12, 2026 and that is expected to become effective on or after February 13, 2026. The company cautions that there is no assurance the Panel will allow continued listing or that it will regain compliance within any time period that may be granted.